EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.
Frequently asked questions
What sector does EirGenix Inc. (6589) operate in?
EirGenix Inc. belongs to the Other sector and operates in the Biotechnology industry.
What is EirGenix Inc. (6589) current stock price?
As of the latest data, EirGenix Inc. stock price is NT$50.80, with a previous close of NT$50.80.
What is EirGenix Inc. (6589) current market capitalization?
EirGenix Inc. market cap is approximately 15.13 billion.
What is EirGenix Inc. (6589) Earnings Per Share (EPS)?
The trailing EPS is -NT$2.46, and the forward EPS is NT$0.57.
Does EirGenix Inc. (6589) pay dividends?
No. EirGenix Inc. does not pay a dividend.
What is EirGenix Inc. (6589) beta (volatility) score?
EirGenix Inc. has a beta of 0.312, indicating lower volatility than the overall market.
